GeroScience

Rapamycin and lifespan in kidney transplant patients who live past their first year

Updated

Abstract

The median survival age for kidney transplant recipients on rapamycin was 64.6 years, similar to 64.3 years for those not on the drug.

  • A total of 4885 kidney transplant recipients were prescribed rapamycin, compared to 6589 who were not.
  • Recipients were followed for a median of 11 years, during which 6443 individuals died.
  • Statistical adjustments were made for differences in age, BMI, diabetes, and 15 other factors.
  • No meaningful improvement in long-term survival was observed with mTOR inhibition in this cohort.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free